Quang Le, PharmD, PhD1, Mallik Greene, PhD2, A. Burak Ozbay, MBA, PhD3, Michael Dore, MD4, A Mark Fendrick, MD5, Paul Limburg, MD, MPH6 1Exact Sciences Corporation, Madison, WI; 2Exact Sciences, Madison, WI; 3Exact Sciences, Lake Forest, IL; 4Durham, NC; 5University of Michigan, Ann Arbor, MI; 6Exact Sciences, Rochester, MN
Introduction: The multi-target stool DNA test (mt-sDNA) is a guideline-recommended, at-home CRC screening option for average-risk individuals. Previously reported cross-sectional adherence to mt-sDNA in a population of commercially and Medicare-insured patients was 66.8%, but the rates in the expanded screening population (following the inclusion of individuals aged 45-49 years) is incompletely defined. The objectives of the study are to update cross-sectional adherence to mt-sDNA testing and to evaluate the adherence rates for different payors and sub-groups.
Methods: This analysis included individuals between ages 45 and 85 years with commercial, Medicaid, or Medicare insurance and shipped an mt-sDNA test by Exact Sciences Laboratories between January 1, 2023, and June 1, 2023. Patient adherence to mt-sDNA is defined as completion and return of the mt-sDNA test kit within 365 days from the initial shipment.
Results: Of 2,142,469 individuals who received a mt-sDNA test kit, overall cross-sectional adherence was 71.2% with an average of 27.3 days from initial shipment date to return of the mt-sDNA test kit. Adherence rates for Medicare, Medicare Advantage, commercial insurance, and Medicaid were 70.1%, 70.1%, 71.2%, and 51.5%, respectively. For age groups 45-49, 50-64, 65-75, and 76-85 years, adherence rates were 69.0%, 68.2%, 73.2%, and 77.3%, respectively. Patients with the highest adherence rates were those who received fully digital outreach, whose mt-sDNA tests were ordered by gastroenterologists, who were Spanish speaking, or who were new or returning to mt-sDNA testing (73.4%, 80.8%, 69.4%, 71.6% and 87.0%, respectively).
Discussion: Data from this large, national sample of insured individuals ages 45-85 years demonstrates high mt-sDNA adherence rates overall and across different health payors and other analyzed subgroups.
Disclosures:
Quang Le: Exact Sciences – Employee.
Mallik Greene: exact sciences – Employee.
A. Burak Ozbay: Exact Sciences – Employee, Stock Options.
Michael Dore indicated no relevant financial relationships.
A Mark Fendrick: Exact Sciences – Advisory Committee/Board Member, Consultant.
Paul Limburg: Exact Sciences Corporation – Consultant, Employee, Stock-publicly held company(excluding mutual/index funds).
Quang Le, PharmD, PhD1, Mallik Greene, PhD2, A. Burak Ozbay, MBA, PhD3, Michael Dore, MD4, A Mark Fendrick, MD5, Paul Limburg, MD, MPH6. P0437 - Cross‑Sectional Adherence With the Multi‑Target Stool DNA Test for Colorectal Cancer Screening Among Four Largest Payors in the Country, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
